{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:52Z","timestamp":1791216532837,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006668","name":"Fondo para la Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Science and Engineering: C"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.msec.2020.111398","type":"journal-article","created":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T10:42:42Z","timestamp":1598092962000},"page":"111398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody \u2013 Bevacizumab \u2013 and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies"],"prefix":"10.1016","volume":"119","author":[{"given":"Mar\u00eda Lina","family":"Formica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Legeay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Bejaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Gabriel","family":"Montich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Ver\u00f3nica","family":"Ullio Gamboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago Daniel","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.msec.2020.111398_bb0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1023\/A:1016121319668","article-title":"A novel phase inversion-based process for the preparation of lipid nanocarriers","volume":"19","author":"Heurtault","year":"2002","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.msec.2020.111398_bb0010","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12041-009-0068-0","article-title":"Mediators of ocular angiogenesis","volume":"88","author":"Qazi","year":"2009","journal-title":"J. Genet."},{"key":"10.1016\/j.msec.2020.111398_bb0015","doi-asserted-by":"crossref","unstructured":"Cabral T, Mello LGM, Lima LH, Polido J, Regatieri C V., Belfort R, et al. Retinal and choroidal angiogenesis: a review of new targets. Int J Retin Vitr [Internet]. 2017; 3(1):31. Available from: http:\/\/journalretinavitreous.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s40942-017-0084-9.","DOI":"10.1186\/s40942-017-0084-9"},{"key":"10.1016\/j.msec.2020.111398_bb0020","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/17425247.2016.1227785","article-title":"Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications","volume":"14","author":"Kang-Mieler","year":"2017","journal-title":"Expert Opinion on Drug Delivery"},{"issue":"23","key":"10.1016\/j.msec.2020.111398_bb0025","doi-asserted-by":"crossref","first-page":"10457","DOI":"10.1073\/pnas.92.23.10457","article-title":"Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins","volume":"92","author":"Aiello","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.msec.2020.111398_bb0030","doi-asserted-by":"crossref","unstructured":"Liu C-H, Wang Z, Sun Y, Chen J. Animal models of ocular angiogenesis: from development to pathologies. FASEB J [Internet]. 2017;fj.201700336R. Available from: http:\/\/www.fasebj.org\/lookup\/doi\/https:\/\/doi.org\/10.1096\/fj.201700336R.","DOI":"10.1096\/fj.201700336R"},{"key":"10.1016\/j.msec.2020.111398_bb0035","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.msec.2019.01.036","article-title":"Chitosan grafted-poly(ethylene glycol) methacrylate nanoparticles as carrier for controlled release of bevacizumab","volume":"98","author":"Savin","year":"2019","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"issue":"14","key":"10.1016\/j.msec.2020.111398_bb0040","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMp068185","article-title":"The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration","volume":"355","author":"Steinbrook","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msec.2020.111398_bb0045","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/786870","article-title":"Anti-VEGF treatment strategies for wet AMD","volume":"2012","author":"Kovach","year":"2012","journal-title":"Journal of Ophthalmology"},{"issue":"6","key":"10.1016\/j.msec.2020.111398_bb0050","doi-asserted-by":"crossref","first-page":"857","DOI":"10.5301\/ejo.5000299","article-title":"Accessibility as a conditioning factor in treatment for exudative age-related macular degeneration","volume":"23","author":"Real","year":"2013","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.msec.2020.111398_bb0055","doi-asserted-by":"crossref","unstructured":"Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, et al. Clinical effectiveness of intravitreal therapy with ranibizumab vs Aflibercept vs bevacizumab for macular edema secondary to central retinal vein occlusion: a randomized clinical trial. JAMA Ophthalmol [Internet]. 2019 Aug 29; Available from: https:\/\/doi.org\/https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.3305.","DOI":"10.1001\/jamaophthalmol.2019.3305"},{"issue":"10","key":"10.1016\/j.msec.2020.111398_bb0060","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1167\/iovs.17-21813","article-title":"Role of the Fc region in the vitreous half-life of anti-VEGF drugs","volume":"58","author":"Joo","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"7","key":"10.1016\/j.msec.2020.111398_bb0065","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1167\/iovs.18-24024","article-title":"Anti-CD160, alone or in combination with Bevacizumab, is a potent inhibitor of ocular neovascularization in rabbit and monkey models","volume":"59","author":"Menguy","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"3","key":"10.1016\/j.msec.2020.111398_bb0070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1208\/s12248-010-9183-3","article-title":"Ocular drug delivery","volume":"12","author":"Gaudana","year":"2010","journal-title":"AAPS J"},{"key":"10.1016\/j.msec.2020.111398_bb0075","doi-asserted-by":"crossref","unstructured":"Yu Y, Lau LCM, Lo AC, Chau Y. Injectable chemically crosslinked hydrogel for the controlled release of bevacizumab in vitreous: a 6-month in vivo study. Transl Vis Sci Technol [Internet]. 2015;4(2):5. Available from: http:\/\/tvstjournal.org\/doi\/https:\/\/doi.org\/10.1167\/tvst.4.2.5.","DOI":"10.1167\/tvst.4.2.5"},{"issue":"9","key":"10.1016\/j.msec.2020.111398_bb0080","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1167\/iovs.15-17108","article-title":"Design and pharmacokinetic characterization of novel antibody formats for ocular therapeutics","volume":"56","author":"Gadkar","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"6","key":"10.1016\/j.msec.2020.111398_bb0085","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1167\/iovs.16-19204","article-title":"Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model","volume":"57","author":"Park","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"9","key":"10.1016\/j.msec.2020.111398_bb0090","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/IAE.0b013e3181b20eed","article-title":"Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration","volume":"29","author":"Chang","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.msec.2020.111398_bb0095","first-page":"355","article-title":"Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2014","journal-title":"International Journal of Ophthalmology"},{"issue":"4","key":"10.1016\/j.msec.2020.111398_bb0100","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/eye.2014.329","article-title":"Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-trap in a rabbit model","volume":"29","author":"Park","year":"2015","journal-title":"Eye (Lond)."},{"issue":"4","key":"10.1016\/j.msec.2020.111398_bb0105","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/1060028014568006","article-title":"Comparative effectiveness of intravitreal bevacizumab with or without triamcinolone acetonide for treatment of diabetic macular edema","volume":"49","author":"Jin","year":"2015","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.msec.2020.111398_bb0110","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10792-017-0496-4","article-title":"Intravitreal bevacizumab alone or combined with 1 mg triamcinolone in diabetic macular edema: a randomized clinical trial","volume":"38","author":"Riazi-Esfahani","year":"2018","journal-title":"Int. Ophthalmol."},{"issue":"19","key":"10.1016\/j.msec.2020.111398_bb0115","first-page":"3471","article-title":"Intravitreal bevacizumab with or without triamcinolone acetonide for diabetic macular edema: a meta-analysis of randomized controlled trials","volume":"127","author":"Liu","year":"2014","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.msec.2020.111398_bb0120","doi-asserted-by":"crossref","unstructured":"Formica ML, Ullio Gamboa G V, T\u00e1rtara LI, Luna JD, Benoit JP, Palma SD. Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications. Int J Pharm [Internet]. 2020;573:118795. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0378517319308403.","DOI":"10.1016\/j.ijpharm.2019.118795"},{"issue":"33","key":"10.1016\/j.msec.2020.111398_bb0125","doi-asserted-by":"crossref","first-page":"4978","DOI":"10.1016\/j.biomaterials.2007.05.014","article-title":"Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab\u2019 fragments","volume":"28","author":"B\u00e9duneau","year":"2007","journal-title":"Biomaterials."},{"key":"10.1016\/j.msec.2020.111398_bb0130","doi-asserted-by":"crossref","unstructured":"Bourseau-Guilmain E, B\u00e9jaud J, Griveau A, Lautram N, Hindr\u00e9 F, Weyland M, et al. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int J Pharm [Internet]. 2012;423(1):93\u2013101. Available from: http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1016\/j.ijpharm.2011.06.001.","DOI":"10.1016\/j.ijpharm.2011.06.001"},{"issue":"3","key":"10.1016\/j.msec.2020.111398_bb0135","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jconrel.2013.06.014","article-title":"A new tool to ensure the fluorescent dye labeling stability of nanocarriers: a real challenge for fluorescence imaging","volume":"170","author":"Bastiat","year":"2013","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.msec.2020.111398_bb0140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2174\/1389201015666140619120834","article-title":"Quantification, microbial contamination, physico-chemical stability of repackaged bevacizumab stored under different conditions","volume":"15","author":"Signorello","year":"2014","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.msec.2020.111398_bb0145","doi-asserted-by":"crossref","unstructured":"Adem YT, Schwarz KA, Duenas E, Patapoff TW, Galush WJ, Esue O. Auristatin antibody drug conjugate physical instability and the role of drug payload. Bioconjug Chem [Internet] 2014 Apr 16;25(4):656\u2013664. Available from: http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1021\/bc400439x.","DOI":"10.1021\/bc400439x"},{"key":"10.1016\/j.msec.2020.111398_bb0150","doi-asserted-by":"crossref","unstructured":"Le Roux G, Moche H, Nieto A, Benoit JP, Nesslany F, Lagarce F. Cytotoxicity and genotoxicity of lipid nanocapsules. Toxicol Vitr [Internet] 2017;41:189\u2013199. Available from: http:\/\/dx.doi.org\/https:\/\/doi.org\/10.1016\/j.tiv.2017.03.007.","DOI":"10.1016\/j.tiv.2017.03.007"},{"issue":"1","key":"10.1016\/j.msec.2020.111398_bb0155","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1080\/10717544.2018.1507061","article-title":"Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma","volume":"25","author":"Clavreul","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.msec.2020.111398_bb0160","doi-asserted-by":"crossref","unstructured":"Bourseau-Guilmain E, B\u00e9jaud J, Griveau A, Lautram N, Hindr\u00e9 F, Weyland M, et al. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Int J Pharm [Internet] 2012;423(1):93\u2013101. Available from: http:\/\/eutils.ncbi.nlm.nih.gov\/entrez\/eutils\/elink.fcgi?dbfrom=pubmed&id=21683129&retmode=ref&cmd=prlinks.","DOI":"10.1016\/j.ijpharm.2011.06.001"},{"issue":"10","key":"10.1016\/j.msec.2020.111398_bb0165","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1021\/bc400182x","article-title":"Investigation into temperature-induced aggregation of an antibody drug conjugate","volume":"24","author":"Beckley","year":"2013","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.msec.2020.111398_bb0170","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jps.24338","article-title":"Characterization of cysteine-linked conjugation profiles of immunoglobulin G1 and immunoglobulin G2 antibody-drug conjugates","volume":"104","author":"Wiggins","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.msec.2020.111398_bb0175","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jps.21104","article-title":"Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies","volume":"97","author":"Ionescu","year":"2008","journal-title":"J. Pharm. Sci."},{"issue":"9","key":"10.1016\/j.msec.2020.111398_bb0180","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1021\/bc900434c","article-title":"Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes","volume":"21","author":"Wakankar","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.msec.2020.111398_bb0185","doi-asserted-by":"crossref","unstructured":"Soares DCF, de Paula Oliveira DC, Barcelos LS, Barbosa AS, Vieira LC, Townsend DM, et al. Antiangiogenic activity of PLGA-Lupeol implants for potential intravitreal applications. Biomed Pharmacother [Internet]. 2017;92:394\u2013402. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0753332217314592.","DOI":"10.1016\/j.biopha.2017.05.093"},{"key":"10.1016\/j.msec.2020.111398_bb0190","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1756-9966-31-37","article-title":"Enhancement of radiation response with bevacizumab","volume":"31","author":"Hoang","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.msec.2020.111398_bb0195","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.2014.283","article-title":"Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90alpha in human colorectal cancer","volume":"111","author":"Lee","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.msec.2020.111398_bb0200","unstructured":"Battaglia L, Gallarate M, Peira E, Chirio D, Solazzi I, Giordano SMA, et al. Bevacizumab loaded solid lipid nanoparticles prepared by the coacervation technique: preliminary in vitro studies. Nanotechnology [Internet]. 2015;26(25):255102. Available from: http:\/\/stacks.iop.org\/0957-4484\/26\/i=25\/a=255102?key=crossref.94bac150ba529c49acde6ca4aa65d9e9."},{"issue":"7","key":"10.1016\/j.msec.2020.111398_bb0205","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/lsm.21109","article-title":"Antiangiogenesis agents avastin and erbitux enhance the efficacy of photodynamic therapy in a murine bladder tumor model","volume":"43","author":"Bhuvaneswari","year":"2011","journal-title":"Lasers Surg. Med."},{"key":"10.1016\/j.msec.2020.111398_bb0210","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s10637-014-0129-y","article-title":"Effects of the combination of TRC105 and bevacizumab on endothelial cell biology","volume":"32","author":"Liu","year":"2014","journal-title":"Investigational New Drugs. New York"},{"key":"10.1016\/j.msec.2020.111398_bb0215","doi-asserted-by":"crossref","unstructured":"Thakur SS, Shenoy SK, Suk JS, Hanes JS, Rupenthal ID. Validation of hyaluronic acid-agar-based hydrogels as vitreous humor mimetics for in vitro drug and particle migration evaluations. Eur J Pharm Biopharm [Internet]. 2020;148:118\u2013125. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0939641120300199.","DOI":"10.1016\/j.ejpb.2020.01.008"}],"container-title":["Materials Science and Engineering: C"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928493120333166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928493120333166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T13:04:19Z","timestamp":1760533459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928493120333166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":43,"alternative-id":["S0928493120333166"],"URL":"https:\/\/doi.org\/10.1016\/j.msec.2020.111398","relation":{},"ISSN":["0928-4931"],"issn-type":[{"value":"0928-4931","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody \u2013 Bevacizumab \u2013 and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies","name":"articletitle","label":"Article Title"},{"value":"Materials Science and Engineering: C","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msec.2020.111398","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111398"}}